首頁 > 市場調查報告書 > 醫療設備

體外診斷

市場調查報告書

商品編碼

1498582

基因檢測市場規模、佔有率、成長分析、按產品類型、按技術、按測試類型、按方法、按最終用戶、按地區 - 行業預測，2024-2031 年

Genetic Testing Market Size, Share, Growth Analysis, By Product, By Technology, By Testing Type, By Methods, By End-User, By Region - Industry Forecast 2024-2031

出版日期: 2024年06月16日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2022年基因檢測市場規模估值為60.8億美元，從2023年的74.2億美元成長到2031年的364億美元，預計在預測期內（2024-2031年）將以22%的複合年成長率成長。

基因檢測在癌症治療中變得越來越重要，包括風險評估、篩檢、降低風險和治療策略。定序技術的進步和成本的降低已將基因檢測推入腫瘤學的主流。流行病學研究不斷揭示與各種基因相關的癌症風險，而指南則為 40 多個基因的致病性變異 (PV) 提供篩檢和預防建議。種系檢測結果可能會影響治療決策，例如 PARP 抑制劑正在核准用於治療 BRCA1/2 基因突變的乳癌、胰臟癌、攝護腺癌和卵巢。國家醫學圖書館根據分析有效性、臨床有效性和臨床效用評估基因測試，確保穩健的評估標準。在全球範圍內，儘管主要零售商提供的直接面對消費者的套件基因檢測存在監管複雜性和成本等挑戰，但由於技術創新、疾病意識增強和人口老齡化，市場正在擴大。

市場概況
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 義大利
- 英國
- 其他歐洲國家地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲 (MEA)
- 海灣合作理事會國家
- 南非
- 其他中東/非洲地區

競爭格局

前5名企業對比
主要企業市場定位（2023年）
主要市場參與者所採取的策略
近期市集活動
主要企業市場佔有率（2023年）

主要企業簡介

Illumina, Inc.（US）
Thermo Fisher Scientific, Inc.（US）
Qiagen NV（Netherlands）
Myriad Genetics, Inc.（US）
Invitae Corporation（US）
BGI Group（China）
Eurofins Scientific SE（Europe）
F. Hoffmann-La Roche AG（Switzerland）
PerkinElmer, Inc.（US）
Becton, Dickinson and Company（US）
Agilent Technologies, Inc.（US）
Bio-Rad Laboratories, Inc.（US）
23andMe, Inc.（US）
Ancestry.com LLC（US）
GeneDx, Inc.（US）
Counsyl, Inc.（US）
Natera, Inc.（US）
Veracyte, Inc.（US）
Guardant Health, Inc.（US）
Caris Life Sciences.（US）

簡介目錄

Product Code: SQMIG35H2074

Genetic Testing Market size was valued at USD 6.08 billion in 2022 and is poised to grow from USD 7.42 billion in 2023 to USD 36.40 billion by 2031, growing at a CAGR of 22% in the forecast period (2024-2031).

Genetic testing in cancer care is increasingly pivotal, encompassing risk assessment, screening, risk mitigation, and treatment strategies. Advances in sequencing technologies and reduced costs have propelled genetic testing into mainstream oncology. Epidemiological studies continually uncover cancer risks associated with various genes, while guidelines provide screening and prevention recommendations for pathogenic variants (PVs) in over 40 genes. Germline test results increasingly influence treatment decisions, exemplified by the approval of PARP inhibitors for breast, pancreatic, prostate, and ovarian cancers in individuals with BRCA1/2 mutations. The National Library of Medicine evaluates genetic tests based on analytical validity, clinical validity, and clinical utility, ensuring robust assessment standards. Globally, the market is expanding due to technological innovations, heightened disease awareness, and ageing populations, despite challenges like regulatory complexities and costs associated with direct-to-consumer genetic testing kits available from major retailers.

Top-down and bottom-up approaches were used to estimate and validate the size of the Genetic Testing Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Genetic Testing Market Segmental Analysis

The genetic testing market is segmented based on testing type, technology, application, and region. In terms of products, the market is segmented into consumables, equipment, and software and services. Based on technology, the market is segmented into next-generation sequencing, polymerase chain reaction, fluorescence in situ hybridization, chemiluminescence immunoassay, and others. Based on testing type, the market is segmented into predictive testing and presymptomatic testing, carrier testing, prenatal and newborn testing, preimplantation testing, diagnostic testing, pharmacogenomic testing, nutrigenomic testing, and forensic testing. Based on methods, the market is segmented into molecular genetic testing, cytogenetic testing, chromosomal genetic testing, biochemical genetic testing, and others. Based on end users, the market is segmented into hospitals, clinical laboratories, and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the Genetic Testing Market

The burgeoning growth of the global genetic testing market is poised to be significantly bolstered by the rising prevalence of genetic and rare disorders worldwide. An illustrative example is the European Union, where approximately 36 million people, exceeding the population of New York City, contend with rare diseases. The EU confronts over 6000 distinct rare diseases, underscoring the complex healthcare landscape. Notably, 80% of these conditions stem from genetic factors, with 70% manifesting in childhood, highlighting the urgent need for early detection and intervention measures. This scenario emphasizes the pivotal role of genetic testing in addressing these challenges and improving patient outcomes through timely identification and management strategies.

Restraints in the Genetic Testing Market

An anticipated challenge that could impede market growth is the high cost of genetic testing. According to the National Library of Medicine, prices for genetic tests vary widely, ranging from less than $100 to over $2,000, depending on their complexity and breadth. Additional costs may arise when multiple tests are needed or when testing extends to multiple family members to achieve meaningful clinical outcomes. Therefore, the substantial financial investment required for these tests presents a significant barrier to widespread market accessibility and adoption, potentially limiting the reach of genetic testing technologies to broader populations and healthcare applications.

Market Trends of the Genetic Testing Market

Personalized medicine is transforming healthcare by utilizing an individual's genetic makeup to inform decisions on disease prevention, diagnosis, and treatment. This approach customizes medical interventions to match each patient's biological characteristics, leading to significant cost efficiencies in healthcare delivery. By identifying genetic markers influencing drug reactions and treatment outcomes, therapies can be optimized for better safety and effectiveness. This trend is anticipated to persist and evolve in the coming years, promising a future where healthcare interventions are increasingly tailored to the unique genetic profiles of patients, thereby enhancing overall health outcomes and reducing unnecessary medical expenses.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Technology Analysis
Pricing Analysis
Value Chain Analysis
Ecosystem of the Market
Supply Chain Analysis
Start-up Analysis
Regulatory Landscape
Innovation Matrix
Top Investment Analysis
Key Success Factor
Market Attractive Index
Degree of Competition

Genetic Testing Market by Product

Market Overview
Consumables
Equipment
Software and Services

Genetic Testing Market by Technology

Market Overview
Next-generation Sequencing
Polymerase Chain Reaction
Fluorescence In Situ Hybridization
Chemiluminescence Immunoassay
Others

Genetic Testing Market by Testing Type

Market Overview
Predictive Testing and Presymptomatic Testing
Carrier Testing
Prenatal and Newborn Testing
Preimplantation Testing
Diagnostic Testing
Pharmacogenomic Testing
Nutrigenomic Testing
Forensic Testing

Genetic Testing Market by Methods

Market Overview
Molecular Genetic Testing
Chromosomal Genetic Testing
Biochemical Genetic Testing
Others

Genetic Testing Market by End Users

Market Overview
Hospitals
Clinical Laboratories
Others

Genetic Testing Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- Italy
- UK
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Illumina, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Qiagen N.V. (Netherlands)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Myriad Genetics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Invitae Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BGI Group (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eurofins Scientific SE (Europe)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
PerkinElmer, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Becton, Dickinson and Company (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Agilent Technologies, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bio-Rad Laboratories, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
23andMe, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ancestry.com LLC (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GeneDx, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Counsyl, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Natera, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Veracyte, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Guardant Health, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Caris Life Sciences. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments